Abstract

LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
Kelly S Oliner ... Roger Sidhu
Journal of Clinical Oncology | VOL. 31
Kelly S Oliner, et. al.Kelly S Oliner ... Roger Sidhu
20 May 2013
FOLFOX4 plus cetuximab administered weekly or every two weeks in first-line treatment of patients with KRAS and NRAS wild-type (wt) metastatic colorectal cancer (mCRC).
Klaus Kaczirek ... Christoph Zielinski
Journal of Clinical Oncology | VOL. 32
Klaus Kaczirek, et. al.Klaus Kaczirek ... Christoph Zielinski
20 Jan 2014
KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
Buthaina Al Tarawneh ... Laila Owaidi
PloS one | VOL. 14
Buthaina Al Tarawneh, et. al.Buthaina Al Tarawneh ... Laila Owaidi
27 Dec 2019
Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka
Md Maruf Ahmed Molla ... Shirazum Monira Mili
Advances in Cancer Biology - Metastasis | VOL. 5
Md Maruf Ahmed Molla, et. al.Md Maruf Ahmed Molla ... Shirazum Monira Mili
19 Jul 2022
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Re: Parker CC, Petersen PM, Cook AD, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial [NCT00541047]. Ann Oncol. 2024 Apr 5:S0923-7534(24)00105-4
Elio Mazzone ... Francesco Montorsi
Annals of Oncology | VOL. -
Elio Mazzone, et. al.Elio Mazzone ... Francesco Montorsi
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
View more papers